宣泰医药：预计2025年年度实现归属于母公司所有者的净利润4507.00万元至5408.00万元

Core Viewpoint - Xuantai Pharmaceutical announced a significant decline in expected net profit and revenue for the year 2025 compared to the previous year, indicating potential challenges ahead for the company [1] Financial Performance - The company expects a net profit attributable to shareholders of between 45.07 million and 54.08 million yuan for 2025, representing a decrease of 73.62 million to 82.63 million yuan year-on-year, which translates to a decline of 57.65% to 64.71% [1] - Projected operating revenue for 2025 is estimated to be between 393.83 million and 472.60 million yuan, reflecting a decrease of 39.01 million to 117.79 million yuan compared to the previous year, equating to a year-on-year decline of 7.63% to 23.02% [1]